



Saurabh Dahiya, MD, FACP

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Medicine - Blood & Marrow Transplantation

CLINICAL OFFICE (PRIMARY)

- **Blood and Marrow Transplant Program**

300 Pasteur Dr Rm H0101

MC 5623

Stanford, CA 94305

Tel (650) 723-0822 **Fax** (650) 498-6919

Bio

BIO

Dr. Saurabh Dahiya is a cancer specialist board-certified in internal medicine, hematology, and medical oncology. He serves as Associate Professor of Medicine at Stanford University School of Medicine and Clinical Director of Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy, where he provides patient-centered care for individuals with cancer.

Dr. Dahiya's research focuses on advancing cellular immunotherapies for hematologic malignancies, including CAR T-cell platforms and next-generation multiantigen targeting strategies for lymphoma. His work aims to address high tumor bulk disease and develop novel cell therapy approaches that enhance durability and response in hematologic cancers. He leads multiple investigator-initiated and industry-sponsored trials in cellular immunotherapy with a focus on translating correlative research insights into improved patient outcomes.

He has authored more than 100 peer-reviewed publications in journals such as The New England Journal of Medicine, Nature Medicine, Journal of Clinical Oncology, Blood, and Blood Advances. Dr. Dahiya serves as Hematology Lead Editor for Critical Reviews in Oncology and Hematology and is an active member of ASH, ASTCT, and ASCO. Before joining Stanford, he was on faculty at the University of Maryland's Greenebaum Comprehensive Cancer Center, where he helped develop the Cellular Immunotherapy Program.

CLINICAL FOCUS

- Blood and Marrow Transplantation
- Cellular Therapy
- Hematology

ACADEMIC APPOINTMENTS

- Associate Professor - University Medical Line, Medicine - Blood & Marrow Transplantation

PROFESSIONAL EDUCATION

- Board Certification: Hematology, American Board of Internal Medicine (2024)
- Board Certification: Medical Oncology, American Board of Internal Medicine (2024)
- Fellowship: Cleveland Clinic Foundation (2013) OH
- Fellowship: Stanford University Bone Marrow Transplant Fellowship (2017) CA
- Fellowship: Baystate Medical Center (2016) MA
- Residency, Baystate Medical Center/Tufts University School of Medicine , Internal Medicine Residency (2012)
- Internship: Western Reserve Care System (2010) OH
- Medical Education: Maulana Azad Medical College (2008) India

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CLINICAL TRIALS

- EAP for Subjects Receiving Lisocabtagene Maraleucl That is Nonconforming for Commercial Release, Recruiting
- Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel, Recruiting
- LTFU in Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells, Recruiting
- Phase 1/2 KITE-363 / KITE-753 Autologous Anti-CD19/CD20 CAR T-Cell Therapies in R/R B-Cell Lymphoma, Recruiting
- Phase I GD2 CAR T Cells for H3K27M-mutant Diffuse Midline Glioma (DMG), Recruiting
- Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing, Recruiting
- Phase Ib Axicabtagene Ciloleucl Reinfusion(Axi-Cel-2) in Relapsed/Refractory 2nd Line High-Risk NHL, Not Recruiting
- Phase II Open-Label BasketStudy Brexucabtagene Autoleucl in Adult Rare B-Cell Malignancies(ZUMA-25), Not Recruiting
- Phase II/III NKTR-255 vsPlaceboFollowing CD19-Directed CAR-T CellTherapy in R/R LargeB-Cell Lymphoma, Not Specified

Publications

PUBLICATIONS

- **Real-World Experience With a ZUMA-1 Cohort 4 Adopted Approach to CRS and ICANS in CAR-T Recipients.** *European journal of haematology*
Sainatham, C., Goloubeva, O., Margiotta, P., Alharthy, H., Patel, I., Gaddipati, G., Bukhari, A., Law, J., Lee, S. T., Kocoglu, M., Yared, J., Hardy, N., Nelson, et al
2026
- **Post CAR-T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse.** *American journal of hematology*
Ananth, S., Agarwal, N., Sahaf, B., Jacob, A., Lee, L. W., Simmons, H., Kirsch, I., Bharadwaj, S., Weng, W. K., Smith, M., Dahiya, S., Miklos, D., Frank, et al
2026
- **Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas.** *Blood neoplasia*
Mirza, A. S., Hosing, C., Foss, F., Kim, S., Moskop, A., Oloyede, T., Abid, M. B., Afrough, A., Ahmed, S., Badar, T., Barba, P., Bhatt, V. R., Brown, et al
2026; 3 (2): 100187
- **Brexu-cel plus dasatinib: Safety and feasibility of dasatinib pulses after brexucabtagene autoleucl to modulate CAR T cell activity in relapsed/refractory B cell acute lymphoblastic leukemia**

Jeyakumar, N., Shiraz, P., Weber, E., Kanegai, A., Wagner, C., Ramakrishnan, A., Sahaf, B., Frank, M., Dahiya, S., Smith, M., Sidana, S., Mackall, C., Miklos, et al
AMER ASSOC CANCER RESEARCH.2026

- **Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy.** *Blood cancer journal*
Rana, M. S., Fernandez-Pol, S., Jensen, A., Hovanky, V., Velayati, A., Oak, J. S., Silva, O., Ames, E., Muffly, L. S., Sahaf, B., Arai, S., Kennedy, V. E., Bharadwaj, et al
2026
- **Superior Chronic GVHD-Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation.** *Transplantation and cellular therapy*
Molina, A., Bubb, Q. R., Srinagesh, H. K., Yee, R., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, E., Mikkilineni, et al
2026
- **Early Steroid and Anakinra Use to Manage Axicabtagene Ciloleucl Toxicity Reduces the Total Duration of CRS and ICANS.** *Blood advances*
Wang, W. L., Lee, D., Cheung, E., Jensen, A., Rana, M. S., Goyal, A., Hamilton, M. P., Ghalehsari, N., Latchford, T., Scott, B. J., Mallampet, J., Heng, E., Khan, et al
2026
- **Real-world outcomes for isocabtagene maraleucl in patients with relapsed or refractory large B-cell lymphoma.** *Blood*
Crombie, J. L., Ahmed, S., Frigault, M. J., Hunter, B. D., Palomba, M. L., Mirza, A. S., Lunning, M. A., Egin, O., Odstroil Bobillo, M. S., Kallam, A., Kambhampati Thiruvengadam, S., Lee, D., Dahiya, et al
2026
- **A Phase 1 Study of KITE-753 or KITE-363 in Patients with Relapsed/Refractory B-cell Lymphoma: Initial Safety and Preliminary Efficacy of KITE-753 and Updated Results of KITE-363**
Dahiya, S., Ulrickson, M. L., Yared, J. A., Reagan, P. M., Voorhees, T., Reshef, R., Turtle, C. J., Bachier-Rodriguez, L., Kersten, M., Topp, M. S., Simmons, G. L., Sanderson, R., Nastoupil, et al
ELSEVIER SCIENCE INC.2026: S64-S65
- **Developing Comprehensive Strategies for Managing Behaviorally Dysregulated Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) in Patients Undergoing Chimeric Antigen Receptor (CAR) T cell Therapy**
Latchford, T. M., Davis, B., Scott, B. J., Dahiya, S., Fishman, D., Lahijani, S.
ELSEVIER SCIENCE INC.2026
- **Impact of Social Determinants of Health on Access to CAR-T Therapy and Outcomes in Multiple Myeloma Patients**
Rana, M., Kaveh, N., Jensen, A., Kennedy, V. E., Weng, W., Smith, M., Shiraz, P., Jandir, N., Latchford, T. M., Frank, M., Bharadwaj, S., Dahiya, S., Miklos, et al
ELSEVIER SCIENCE INC.2026
- **Characterization and Outcomes of Switching Tacrolimus to Sirolimus in Patients with Transplant-Associated Thrombotic Microangiopathy**
Kennedy, V. E., Lauer, M., Shiraz, P., Arai, S., Johnston, L., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Lowsky, R., Meyer, E. H., Mikkilineni, L., Muffly, et al
ELSEVIER SCIENCE INC.2026
- **AI-Quantified Patient Frailty Predicts Clinical Response to CAR-T**
Smith, C. J., Fettahoglu, A., Johnston, A., Smith, B. R., Mikkilineni, L., Sidana, S., Weng, W., Frank, M., Dahiya, S., Smith, M., Chaudhari, A., Miklos, D. B., Boutin, et al
ELSEVIER SCIENCE INC.2026
- **Phase II Interim Results for Rapcabtagene Autoleucl (YTB323) in Patients with First-Line, High-Risk Large B-cell Lymphoma**
Westin, J., Chavez, J. C., Schuster, S. J., Vucinic, V., Young, P. A., Johnson, P., Bramanti, S., Rambaldi, A., Meijde, J., Kato, K., Sancho, J., Kwon, M., Solano, et al
ELSEVIER SCIENCE INC.2026: S48-S49
- **Enhancing the Safety of Ciltacabtagene Autoleucl in Relapsed Multiple Myeloma (MM):Identification of Potentially Modifiable Risk-Factors Associated with Delayed Neurotoxicity and Non-Relapse Mortality**
Sidana, S., Reid, B., Dima, D., Peres, L. C., Gaballa, M., Banerjee, R., Pasvolsky, O., Afrough, A., Dillard, C., Ferreri, C., Atrash, S., Varga, C., Portuguese, et al
ELSEVIER SCIENCE INC.2026: S11-S12

- **Patient Characteristics, Toxicity, and Response after Real World Administration of Obecabtagene Autoleucl and Brexucabtagene Autoleucl for Relapsed Acute Lymphoblastic Leukemia: A Rocca Analysis**
Molina, A., Shiraz, P., Kanegai, A., Fraser, A., Kordek, D., Wagner, C., Danley, L., Ramakrishnan, A., Daghigh, H., Huang, Y., Dhapola, G., Siddiqui, A., Arai, et al
ELSEVIER SCIENCE INC.2026: S27
- **Treatment kinetics and local response during and after bridging radiotherapy prior to CAR-T cell therapy for lymphomas.** *Leukemia & lymphoma*
Klebaner, D., Park, N. J., Marar, M., Frank, M., Hiniker, S. M., Hoppe, R. T., Schroers-Martin, J., Advani, R. H., Alizadeh, A. A., Bharadwaj, S., Miklos, D., Dahiya, S., Binkley, et al
2025: 1-8
- **Mapping the immune orchestra of zamtocabtagene autoleucl in primary CNS lymphoma.** *Haematologica*
Lee, D., Dahiya, S.
2025
- **Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.** *Blood cancer discovery*
Srinagesh, H. K., Kramer, A. M., Baird, J. H., Reschke, A., Sahaf, B., Cancilla, J., Syal, S., Su, Y. J., Agarwal, N., Jensen, A. M., Schultz, L. M., Jeyakumar, N., Ramakrishna, et al
2025
- **Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation**
Molina, A., Bubb, Q., Yee, R., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, E., Mikkilineni, L., Lowsky, et al
ELSEVIER.2025: 2494-2495
- **CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphoma**
Kramer, A., Murty, T., Chen, Y., Rodrigues, K., Hamilton, M., Desai, M., Kuo, A., Ehlinger, Z., Reynolds, W., Srinagesh, H., Tsui, K., Rietberg, S., Mo, et al
ELSEVIER.2025: 566-567
- **Rapcabtagene autoleucl (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results**
Westin, J., Chavez, J., Schuster, S. J., Vucinic, V., Young, P. A., Johnson, P., Bramanti, S., Rambaldi, A., Meijide, J., Kato, K., Sancho, J., Kwon, M., Solano, et al
ELSEVIER.2025: 670-671
- **Double-dose axicabtagene ciloleucl (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study**
Lee, D., Rodrigues, K., Rana, M., Kozy, K., Salazar, S., Jensen, A., Desai, M., Mallampet, J., Lohman, C., Huang, Y., Kang, X., Tian, F., Mutter, et al
ELSEVIER.2025: 671-672
- **Pre-treatment CD19 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL**
Spiegel, J., Oak, J., Rana, M., Jensen, A., Lee, D., Nguyen-Mau, S., Kong, K., Bornheimer, S., Mikkilineni, L., Muffly, L., Sidana, S., Weng, W., Bharadwaj, et al
ELSEVIER.2025: 5882-5883
- **Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged > 75) with relapsed or refractory multiple myeloma (RRMM)**
Velayati, A., Jensen, A., Dima, D., Rana, M., Peres, L., Shune, L., Reid, B., Pasvolsky, O., Portuguese, A., Abdallah, N., Hosoya, H., Mikkilineni, L., Banerjee, et al
ELSEVIER.2025: 6375-6376
- **Allogeneic HSC and regulatory T cell (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study**
Villar-Prados, A., Kim, P., Sutherland, K., Negrin, R., Arai, S., Frank, M., Johnston, L., Lowsky, R., Miklos, D., Muffly, L., Dahiya, S., Rezvani, A., Sidana, et al
ELSEVIER.2025: 111-112
- **CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity**

- Srinagesh, H., Kramer, A., Hamilton, M., Su, Y., Kozy, K., Jackson, L., Brown, A., Denoble, K., Mavroukakis, S., Lohman, C., Cunanan, K., Agarwal, N., Bharadwaj, et al
ELSEVIER.2025: 4159-4160
- **Rapid peak CAR-T expansion is associated with delayed neurotoxicity following ciltacabtagene autoleucl in multiple myeloma**
Hosoya, H., Velayati, A., Dima, D., Jensen, A., Portuguese, A., Hovanky, V., Mikkilineni, L., Peres, L., Homsy, S., Rana, M., Cancilla, J., Ehlinger, Z., Sahaf, et al
ELSEVIER.2025: 96
 - **Enhancing the safety of ciltacabtagene autoleucl in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality**
Sidana, S., Reid, B., Dima, D., Peres, L., Gaballa, M., Banerjee, R., Pasvolsky, O., Afrough, A., Dillard, C., Ferreri, C., Atrash, S., Varga, C., Portuguese, et al
ELSEVIER.2025: 1034-1035
 - **Redefining post-CD19 CAR T-cell surveillance with ctDNA: Real-world insights from post- axi-cel and liso-cel therapy**
Ananth, S., Mallampet, J., Chang, B., Agarwal, N., Kong, K., Sahaf, B., Serrato, J., Kirsch, I., Jacob, A., Simmons, H., Lee, L., Mackall, C., Weng, et al
ELSEVIER.2025: 941-942
 - **Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post-CAR-T therapy**
Rana, M., Ghalehsari, N., Jensen, A., Lee, D., Park, N., Goyal, A., Hashmi, A., Wang, W., Heng, E., Velayati, A., Dhapola, G., Huang, Y., Sahaf, et al
ELSEVIER.2025: 397-398
 - **Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT**
Jeyakumar, N., Torres, N., Godbole, S., Yamamoto, F., Zhang, B., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, et al
ELSEVIER.2025: 2525-2526
 - **ZUMA-25 preliminary analysis: A Phase 2 study of brexucabtagene autoleucl (brexu-cel) in patients (Pts) with relapsed/refractory (R/R) burkitt lymphoma (BL), substudy C**
Van Dorp, S., Stussi, G., Frustaci, A., Flinn, S., Crees, Z., Baird, J., Mountjoy, L., Dahiya, S., Kutsch, N., Zinzani, P., Lopez-Guillermo, A., Staber, P., Ysebaert, et al
ELSEVIER.2025: 569-570
 - **Patient-reported outcomes (PROs) with lisocabtagene maraleucl (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study**
Karmali, R., Morschhauser, F., Izutsu, K., Palomba, L., Ardeschna, K., Hill, B., Kamdar, M., Schuster, S. J., Pinto, A., Dahiya, S., Bar, M., Strocchia, M., Kumar, et al
ELSEVIER.2025: 709-710
 - **Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL**
Molina, A., Shiraz, P., Kanegai, A., Fraser, A., Kordek, D., Wagner, C., Srinagesh, H., Danley, L., Ramakrishnan, A., Daghigh, H., Huang, Y., Dhapola, G., Siddiqui, et al
ELSEVIER.2025: 514-515
 - **A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363**
Dahiya, S., Ulrickson, M., Yared, J., Reagan, P., Voorhees, T., Reshef, R., Turtle, C., Bachier-Rodriguez, L., Kersten, M., Topp, M. S., Simmons, G., Sanderson, R., Nastoupil, et al
ELSEVIER.2025: 265-266
 - **Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium**
Reshef, R., Jensen, A., Gordillo, C., Reid, B., Dima, D., Peres, L., Gaballa, M., Banerjee, R., Pasvolsky, O., Afrough, A., Dillard, C., Ferreri, C., Atrash, et al
ELSEVIER.2025: 134-135
 - **From response to rupture: Evaluating GI perforation after CD19 CAR-T in LBCL**

Velayati, A., Rana, M., Jensen, A., Lee, D., Ghalehsari, N., Goyal, A., Latchford, T., Wang, W., Heng, E., Weng, W., Smith, M., Bharadwaj, S., Frank, et al
ELSEVIER.2025: 2771-2772

- **Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM)**
Rana, M., Jensen, A., Velayati, A., Hovanky, V., Muffly, L., Sahaf, B., Iberri, D., Liedtke, M., Bharadwaj, S., Kennedy, V., Arai, S., Shiraz, P., Weng, et al
ELSEVIER.2025: 4586-4587
- **CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias.** *Research square*
Hamilton, M. P., Phillips, N., Noordenbos, T., Boegeholz, J., Sugio, T., Sworder, B. J., Alig, S. K., Good, Z., Schroers-Martin, J. G., Tamaresis, J., Esfahani, M. S., Lu, Y., Olsen, et al
2025
- **Rapid Peak CAR-T Expansion is Associated with Delayed Neurotoxicity Following Ciltacabtagene Autoleucl in Multiple Myeloma**
Hosoya, H., Velayati, A., Dima, D., Jensen, A., Portuguese, A., Hovanky, V., Mikkilineni, L., Peres, L., Homsy, S., Rana, M. S., Cancilla, J., Ehlinger, Z., Sahaf, et al
CIG MEDIA GROUP, LP.2025
- **Baseline Metabolic Tumor Volume (MTV) as a Prognostic Marker in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Relapsed/Refractory Large B-Cell Lymphoma**
Rana, M., Ghalehsari, N., Jensen, A., Lee, D., Wang, W., Dahiya, S.
CIG MEDIA GROUP, LP.2025
- **Immune Reconstitution, Vaccine Protection, and Infectious Complications Following BCMA-Targeted CAR-T Therapy in Relapsed/Refractory Multiple Myeloma**
Moscvin, M., Goyal, A., Jensen, A., Epstein, D., Hovanky, V., Mikkilineni, L., Bennett, L., Latchford, T., Arai, S., Bharadwaj, S., Frank, M., Dahiya, S., Muffly, et al
CIG MEDIA GROUP, LP.2025
- **Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of CAR-T Therapy in Relapsed or Refractory Large B-Cell Lymphoma**
Goyal, A., Bharadwaj, S., Lau, E., Jensen, A., Hamilton, M., Lee, C., Sahaf, B., Syal, S., Patil, S., Latchford, T., Dahiya, S.
CIG MEDIA GROUP, LP.2025: S1051-S1052
- **NKTR-255 Enhances Complete Response Following CD19 CAR-T in Patients with Relapsed/Refractory Large B-cell Lymphoma.** *Blood advances*
Ahmed, S., DiPersio, J. F., Essell, J. H., Diefenbach, C., Perales, M. A., Castilla-Llorente, C., Dahiya, S., Liu, Y., Xu, H., Fanton, C., Chaudhry, S., Lee, Z., Marcondes, et al
2025
- **Noncanonical and mortality-defining toxicities of CAR T cell therapy.** *Nature medicine*
Rejeski, K., Hill, J. A., Dahiya, S., Jain, M. D.
2025
- **Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucl and ciltacabtagene autoleucl in a real-world cohort of patients with multiple myeloma.** *Nature communications*
Atanackovic, D., Luetkens, T., Schneider, D., Hu, P., Wang, X., Shetty, A. C., Tallon, L., Patel, I., Singh, R., Gebru, E., Mulatu, R., Omili, D., Yamoah, et al
2025; 16 (1): 6154
- **Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucl (axi-cel) in the US for patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL).**
Furqan, F., Hemmer, M. T., Tees, M., Baird, J. H., Holter-Chakrabarty, J. L., McClune, B. L., Jacobson, C., Dahiya, S., Locke, F. L., Yan, J., Kim, J., Pizzi, E., Bonneh-Barkay, et al
LIPPINCOTT WILLIAMS & WILKINS.2025: 7023
- **A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).**
Dahiya, S., Ulrickson, M., Topp, M. S., Kersten, M., Yared, J., Reagan, P., Reshef, R., Sanderson, R., Voorhees, T., Ahmed, S., Jung, A., Granados, E., Dong, et al
LIPPINCOTT WILLIAMS & WILKINS.2025

- **Fatal Recurrence of IEC-HS Following Autologous Stem Cell Boost in Patients Receiving BCMA CAR-T Cell Therapy.** *Blood advances*
Ananth, S., Torres, N. E., Sahaf, B., Mikkilineni, L., Fernandez-Pol, S., Salmi, D., Negrin, R. S., Shiraz, P., Smith, M., Bharadwaj, S., Weng, W. K., Kennedy, V. E., Dahiya, et al
2025
- **Lisocabtagene Maraleucl for Richter's Transformation-A Case Series.** *EJHaem*
Smith, C. J., Goyal, A., Smith, B. R., Lee, D., Jensen, A., Alexander, J., Smith, M., Frank, M., Dahiya, S., Miklos, D., Bharadwaj, S.
2025; 6 (2): e270011
- **Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucl and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma.** *Experimental hematology & oncology*
Nastoupil, L. J., Bonner, A., Wang, P., Almuallem, L., Desai, J., Farazi, T., Kumar, J., Dahiya, S.
2025; 14 (1): 30
- **Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma.** *Blood*
Samples, L., Sadrzadeh, H., Frigault, M. J., Jacobson, C. A., Hamadani, M., Gurumurthi, A., Strati, P., Shouval, R., Noy, A., Riedell, P. A., Dahiya, S., Maloney, D. G., Till, et al
2025
- **Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease.** *Blood*
Meyer, E., Pavlova, A., Villar-Prados, A., Bader, C. S., Xie, B., Muffly, L., Kim, P., Sutherland, K. C., Bharadwaj, S., Dahiya, S., Frank, M. J., Arai, S., Johnston, et al
2025
- **Effects of an initial anti-CD19 CAR T-cell therapy on subsequent anti-CD22 CAR T-cell manufacturing and clinical outcomes in patients with r/r LBCL.** *Cancer discovery*
Su, Y. J., Kramer, A. M., Hamilton, M. P., Agarwal, N., Srinagesh, H. K., Baird, J. H., Sahaf, B., Kuo, A., Ehlinger, Z. J., Desai, M. H., Rietberg, S. P., Tunuguntla, R., Patel, et al
2025
- **Second Primary Cancer After Chimeric Antigen Receptor-T-Cell Therapy: A Review.** *JAMA oncology*
Patel, S. A., Spiegel, J. Y., Dahiya, S.
2024
- **Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies**
Diaz, J., Dahiya, S., Sillito, F., O'Reilly, M., Rejeski, K., Buecklein, V. L., Subklewe, M., Iacoboni, G., Barba, P., Roddie, C., Locke, F., Spiegel, J. Y., Ali, et al
ELSEVIER.2024: 7239-7240
- **Predictors of Early Safety Outcomes with Axicabtagene Ciloleucl (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)**
Strouse, C., Farooq, U., Shouval, R., Vallurupalli, A., Moskop, A., Jacobson, C. A., Locke, F., Baird, J. H., Strati, P., Patel, D. A., Dahiya, S., Hemmer, M. T., Du, et al
ELSEVIER.2024: 609-610
- **CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma**
Kramer, A., Srinagesh, H., Su, Y., Hamilton, M. P., Levine, K., Migliore, E., Denoble, K., Brown, A. K., Cunanan, K., Agarwal, N., Lohman, C., Mavroukakis, S., Bharadwaj, et al
ELSEVIER.2024: 2064-2066
- **Real-World (RW) Outcomes of Lisocabtagene Maraleucl (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry**
Bobillo, M., Kambhampati, S., Lee, D., Hunter, B. D., Egini, O., Patel, K., Reagan, P. M., Bernasconi, D., Kim, S., Parrilla, C., Krimmel, T., Liu, F., Roy, et al
ELSEVIER.2024: 472
- **NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)**

- Ahmed, S., Dipersio, J. F., Md, J., Diefenbach, C. S., Perales, M., Castilla-Llorente, C., Dahiya, S., Chaudhry, S., Xu, H., Liu, Y., Fanton, C., Lee, Z., Marcondes, et al
ELSEVIER.2024: 2068-2070
- **Point-of-Care Bispectral Electroencephalogram (BSEEG) As a New Tool in Detecting Immune Effector Cell Associated Neurotoxicity (ICANS) in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T)**
Homsy, S., Seki, T., Nguyen, H., Shimura, A., Gorantla, N., Phuong, N., Ghalehsari, N., Velayati, A., Jeyakumar, N., Hamilton, M. P., Kennedy, V. E., Mikkilineni, L., Bharadwaj, et al
ELSEVIER.2024: 7134-7135
 - **Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL**
Muffy, L., Ananth, S., Danley, L., Wagner, C., Kordek, D., Denoble, K., Fraser, A., Egeler, E., Molina, A., Ehlinger, Z., Desai, M., Daghigh, H., Tunuguntla, et al
ELSEVIER.2024: 680
 - **Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged > 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)**
Lee, D., Bharadwaj, S., Rana, M. S., Jensen, A., Wang, W., Ghalehsari, N., Sahaf, B., Mallampet, J., Elkordy, S., Latchford, T., Arai, S., Johnston, L., Hosoya, et al
ELSEVIER.2024: 386-387
 - **Investigating Treatment Kinetics and Local Response during and after Bridging Radiotherapy Prior to CAR-T Cell Therapy for Lymphomas**
Klebaner, D., Park, N., Marar, M., Frank, M. J., Hiniker, S., Hoppe, R. T., Schroers-Martin, J. G., Advani, R. H., Alizadeh, A. A., Bharadwaj, S., Miklos, D. B., Dahiya, S., Binkley, et al
ELSEVIER.2024: 7130-7131
 - **Cost Consequence and Time Toxicity Model for the Treatment of Third-Line or Later (3L+) Follicular Lymphoma (FL) Using Advanced Therapies: A Comparison of Lisocabtagene Maraleucel (liso-cel) with Mosunetuzumab**
Dahiya, S., Saunders, A. C., Kumar, J., Ngantung, W., Saeedian, M.
ELSEVIER.2024: 3651-3652
 - **Idelalisib (Zydelig®) Maintenance in B-Cell Non-Hodgkin's Lymphoma after High Dose Chemotherapy and Autologous Stem Cell Transplantation**
Yared, J. A., Singh, T., Beitinjaneh, A., Rapoport, A. P., Dahiya, S., Atanackovic, D., Hardy, N. M., Kocoglu, M. H., Toth, T., Pineiro, D., Goloubeva, O.
ELSEVIER.2024: 6354-6355
 - **Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma**
Hosoya, H., Jensen, A., Hovanky, V., Homsy, S., Cancelli, J. E., Patil, S., Kennedy, V. E., Bharadwaj, S., Smith, M., Shiraz, P., Frank, M. J., Dahiya, S., Arai, et al
ELSEVIER.2024: 2006-2007
 - **CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up**
Kramer, A., Baird, J. H., Srinagesh, H., Egeler, E., Levine, K., Brown, A. K., Mavroukakis, S., Cunanan, K., Su, Y., Agarwal, N., Hamilton, M. P., Bharadwaj, S., Arai, et al
ELSEVIER.2024: 70-71
 - **Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms**
Hamilton, M., Phillips, N., Lee, D., Ehlinger, Z., Kramer, A., Srinagesh, H., Good, Z., Kang, X., Olsen, M., Liu, C., Tian, F., Sworder, B. J., Hosoya, et al
ELSEVIER.2024: 96-97
 - **Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up**
Nastoupil, L., Dahiya, S., Palomba, M., Garcia-Sancho, A., Reguera, J., Kuruvilla, J., Jaeger, U., Cartron, G., Izutsu, K., Dreyling, M., Kahl, B. S., Ghesquieres, H., Ardeshtna, et al
ELSEVIER.2024: 4387-4390
 - **Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report**

- Wang, J., Bhaskar, S., Adedokun, B., Oluwole, O. O., Metheny, L., Moskop, A., Jacobson, C. A., Shouse, G., Ahmed, S., Ghobadi, A., Dahiya, S., Yan, J., Hu, et al
ELSEVIER.2024: 528
- **Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)**
Lee, D., Kambhampati, S., Bobillo, M., Adedokun, B., Shadman, M., Olson, A. L., Herrera, A. F., Lee, C. J., Jacobson, C. A., Bye, M., Hamadani, M., Kim, S., Dahiya, et al
ELSEVIER.2024: 527-528
 - **Indolent CD8+CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma**
Hosoya, H., Fernandez-Pol, S., Gubatan, J., Ehlinger, Z., Lohman, C., Torres, A., Najidh, S., Kwang, A., Duran, G., Wright, C., Kennedy, V. E., Bharadwaj, S., Smith, et al
ELSEVIER.2024: 4846-4847
 - **PHASE 1 TRIAL RESULTS FOR PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES TREATED WITH ORCA-T CELL THERAPY WITH REDUCED INTENSITY CONDITIONING AND SINGLE AGENT TACROLIMUS**
Villar-Prados, A., Sutherland, K., Negrin, R., Arai, S., Frank, M., Johnston, L., Lowsky, R., Miklos, D., Muffly, L., Dahiya, S., Rezvani, A., Sidana, S., Shiraz, et al
SPRINGER NATURE.2024: 287-288
 - **The National Cancer Institute Clinical Trials Planning Meeting to Address Gaps in Observational and Intervention Trials for Cancer-Related Cognitive Impairment.** *Journal of the National Cancer Institute*
Janelins, M. C., Van Dyk, K., Hartman, S. J., Koll, T. T., Cramer, C. K., Lesser, G. J., Barton, D. L., Mustian, K. M., Wagner, L. I., Ganz, P. A., Cole, P. D., Bakos, A., Root, et al
2024
 - **Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study**
Dahiya, S., Hirayama, A. V., Schuster, S. J., Reguera Ortega, J., Morschhauser, F., Garcia-Sancho, A., Kuruvilla, J., Izutsu, K., Maria Barbui, A., Borchmann, P., Mielke, S., Cartron, G., Ghesquieres, et al
CIG MEDIA GROUP, LP.2024: S462-S463
 - **Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Jain, M. D., Spiegel, J. Y., Nastoupil, L. J., Tamaresis, J., Ghobadi, A., Lin, Y., Lekakis, L., Reagan, P., Oluwole, O., McGuirk, J., Deol, A., Dorritie, K. A., Sehgal, et al
2024: JCO2302786
 - **CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.** *Lancet (London, England)*
Frank, M. J., Baird, J. H., Kramer, A. M., Srinagesh, H. K., Patel, S., Brown, A. K., Oak, J. S., Younes, S. F., Natkunam, Y., Hamilton, M. P., Su, Y. J., Agarwal, N., Chinnasamy, et al
2024
 - **Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.** *Nature medicine*
Morschhauser, F., Dahiya, S., Palomba, M. L., Martin Garcia-Sancho, A., Reguera Ortega, J. L., Kuruvilla, J., Jäger, U., Cartron, G., Izutsu, K., Dreyling, M., Kahl, B., Ghesquieres, H., Ardeschna, et al
2024
 - **A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.** *Blood*
Srinagesh, H. K., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M. P., Egeler, E., Mavroukakis, S., Kuo, A., Cancilla, J., Sahaf, B., Agarwal, N., Kanegai, A. M., Kramer, et al
2024
 - **Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.** *Journal for immunotherapy of cancer*
Bharadwaj, S., Lau, E., Hamilton, M. P., Goyal, A., Srinagesh, H., Jensen, A., Lee, D., Mallampet, J., Elkordy, S., Syal, S., Patil, S., Latchford, T., Sahaf, et al
2024; 12 (7)

- **Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.** *The New England journal of medicine*
Hamilton, M. P., Sugio, T., Noordenbos, T., Shi, S., Bulterys, P. L., Liu, C. L., Kang, X., Olsen, M. N., Good, Z., Dahiya, S., Frank, M. J., Sahaf, B., Mackall, et al
2024; 390 (22): 2047-2060
- **Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.** *Nature medicine*
Morschhauser, F., Dahiya, S., Palomba, M. L., Martin Garcia-Sancho, A., Reguera Ortega, J. L., Kuruvilla, J., Jäger, U., Cartron, G., Izutsu, K., Dreyling, M., Kahl, B., Ghesquieres, H., Ardeshta, et al
2024
- **Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH)**
Smith, C., Simeone, D. M., Grierson, P., Kirtane, K., Morelli, M., Patel, S., Ulrickson, M. L., Dahiya, S., Park, J., Specht, J. M., Fakh, M., Liechty, K. B., Tebbets, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Treatment strategies for progressive immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: case series.** *Haematologica*
Scala, J. J., Eckrich, M. J., Lipak, K., Yates, B., Yuan, C., Wang, H. W., Dahiya, S., Henter, J. I., Huo, J. S., Frank, M. J., Shah, N. N.
2024
- **Management of post-autologous transplant relapse in patients with T-cell lymphomas.** *American journal of hematology*
Veilleux, O., Socola, F., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Shizuru, J., Meyer, E., Muffly, L., Rezvani, A. R., Shiraz, P., Sidana, S., Dahiya, et al
2024
- **CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.** *Blood advances*
Hamilton, M. P., Craig, E., Gentile Sanchez, C., Mina, A., Tamaresis, J., Kirmani, N., Ehlinger, Z., Syal, S., Good, Z., Sworder, B., Schroers-Martin, J., Lu, Y., Muffly, et al
2024
- **Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells.** *Cancer immunology, immunotherapy : CII*
Kline, K., Luetkens, T., Koka, R., Kallen, M. E., Chen, W., Ahmad, H., Omili, D., Iraguha, T., Gebru, E., Fan, X., Miller, A., Dishanthan, N., Baker, et al
2024; 73 (3): 45
- **A novel multicolor fluorescent spot assay for the functional assessment of chimeric antigen receptor (CAR) T-cell products.** *Cytotherapy*
Atanackovic, D., Iraguha, T., Omili, D., Avila, S. V., Fan, X., Kocoglu, M., Gebru, E., Baker, J. M., Dishanthan, N., Dietze, K. A., Oluwafemi, A., Hardy, N. M., Yared, et al
2024
- **Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B-cell lymphoma in an adolescent patient.** *EJHaem*
Lee, D., Goyal, A., Wang, W. L., Ananth, S., Lau, E., Binkley, M. S., Bharadwaj, S., Dahiya, S.
2024; 5 (1): 153-156
- **TRANSCEND FL: phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)**
Borchmann, P., Morschhauser, F., Dahiya, S., Palomba, M., Garcia-Sancho, A., Reguera Ortega, J., Kuruvilla, J., Jaeger, U., Cartron, G., Izutsu, K., Dreyling, M., Kahl, B., Ghesquieres, et al
KARGER.2024: 142-143
- **Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma.** *Blood advances*
Nie, E. H., Su, Y. J., Baird, J. H., Agarwal, N., Bharadwaj, S., Weng, W. K., Smith, M., Dahiya, S., Han, M. H., Dunn, J. E., Kipp, L. B., Miklos, D. B., Scott, et al
2024
- **CCL8/CCL13-producing tumor-associated macrophages linked to poor outcomes after CAR T cell therapy for LBCL** *American Society of Hematology*
Mo, K. C., Yeh, C. Y., Hamilton, M. P., Spiegel, J., Desai, M., Ehlinger, Z., Reynolds, W. D., Yang, E., Ozawa, M. G., Chen, Y., Prabhu, S., Frank, M. J., Muffly, et al

2024

- **Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: Results from the US lymphoma CAR-T consortium.** *Blood advances*
Jain, M. D., Jacobs, M. T., Gao, F., Nastoupil, L. J., Spiegel, J. Y., Lin, Y., Dahiya, S., Lunning, M. A., Lekakis, L. J., Reagan, P. M., Oluwole, O. O., McGuirk, J. P., Deol, et al
2023
- **CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias**
Hamilton, M. P., Sworder, B. J., Alig, S. K., Good, Z., Boegeholz, J., Schroers-Martin, J., Tamaresis, J., Esfahani, M., Lu, Y., Olsen, M., Liu, C., Ehlinger, Z., Desai, et al
AMER SOC HEMATOLOGY.2023
- **Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)**
Bharadwaj, S., Lau, E., Goyal, A., Hamilton, M. P., Srinagesh, H., Jensen, A., Syal, S., Mallampet, J., Latchford, T., Sahaf, B., Weng, W., Smith, M., Maecker, et al
AMER SOC HEMATOLOGY.2023
- **Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection**
Ananth, S., Su, Y., Hamilton, M. P., Agarwal, N., Weng, W., Dahiya, S., Bharadwaj, S., Mallampet, J., Smith, M., Kong, K., Tway, A., Miklos, D. B., Frank, et al
AMER SOC HEMATOLOGY.2023
- **Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)**
Bharadwaj, S., Lau, E., Hashmi, A., Hamilton, M. P., Jensen, A., Goyal, A., Marar, M., Lee, C., Ananth, S., Sahaf, B., Mallampet, J., Ehlinger, Z., Syal, et al
AMER SOC HEMATOLOGY.2023
- **Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus**
Villar-Prados, A., Meyer, E. H., Sutherland, K., Negrin, R. S., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Miklos, D. B., Muffly, L. S., Dahiya, S., Rezvani, A. R., Sidana, et al
AMER SOC HEMATOLOGY.2023
- **TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as SecondLine Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma**
Morschhauser, F., Dahiya, S., Palomba, M., Garcia-Sancho, A., Reguera, J., Kuruvilla, J., Jaeger, U., Cartron, G., Izutsu, K., Dreyling, M., Kahl, B. S., Ghesquieres, H., Ardeschna, et al
AMER SOC HEMATOLOGY.2023
- **Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)**
Cook, M., Shouval, R., Perales, M., Bezerra, E., Niu, A., Dahiya, S., Nastoupil, L. J., Jacobson, C. A., Budde, L., Olson, A. L., Logan, B. R., Hu, Z., Wang, et al
AMER SOC HEMATOLOGY.2023
- **Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL)**
Dahiya, S., Spiegel, J. Y., Lee, D., Mohammed, T., Lutfi, F., Goyal, A., Hana, C., Chavez, J. C., Ionescu, F., Frank, M. J., Bharadwaj, S., Sandoval-Sus, J., Beitinjaneh, et al
AMER SOC HEMATOLOGY.2023
- **Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium**
Spiegel, J. Y., Jain, M. D., Nastoupil, L. J., Tamaresis, J., Ghobadi, A., Lin, Y., Lekakis, L. J., Reagan, P. M., Oluwole, O. O., McGuirk, J. P., Deol, A., Dorritie, K., Sehgal, et al
AMER SOC HEMATOLOGY.2023
- **Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of Chimeric Antigen Receptor-T (CAR T) Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma (LBCL)**

- Goyal, A., Bharadwaj, S., Lee, D., Lau, E., Hamilton, M. P., Jensen, A., Sahaf, B., Syal, S., Patil, S., Cancilla, J. E., Latchford, T., Weng, W., Smith, et al
AMER SOC HEMATOLOGY.2023
- **Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)**
Bharadwaj, S., Lau, E., Goyal, A., Hamilton, M. P., Srinagesh, H., Jensen, A., Syal, S., Mallampet, J., Latchford, T., Sahaf, B., Weng, W., Smith, M., Maecker, et al
AMER SOC HEMATOLOGY.2023
 - **Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection**
Ananth, S., Su, Y., Hamilton, M. P., Agarwal, N., Weng, W., Dahiya, S., Bharadwaj, S., Mallampet, J., Smith, M., Kong, K., Twoy, A., Miklos, D. B., Frank, et al
AMER SOC HEMATOLOGY.2023
 - **Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)**
Bharadwaj, S., Lau, E., Hashmi, A., Hamilton, M. P., Jensen, A., Goyal, A., Marar, M., Lee, C., Ananth, S., Sahaf, B., Mallampet, J., Ehlinger, Z., Syal, et al
AMER SOC HEMATOLOGY.2023
 - **Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus**
Villar-Prados, A., Meyer, E. H., Sutherland, K., Negrin, R. S., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Miklos, D. B., Muffly, L. S., Dahiya, S., Rezvani, A. R., Sidana, et al
AMER SOC HEMATOLOGY.2023
 - **Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma. *Blood cancer journal***
Sidana, S., Hosoya, H., Jensen, A., Liu, L., Goyal, A., Hovanky, V., Sahaf, B., Bharadwaj, S., Latchford, T., Arai, S., Leahy, S., Mei, M., Budde, et al
2023; 13 (1): 158
 - **Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells. *Haematologica***
Kathari, Y. K., Ahmad, H., Kallen, M. E., Koka, R., Omili, D., Iraguha, T., Clement, J., Pham, L., Khalid, M., Fan, X., Gebru, E., Lesho, P., Park, et al
2023
 - **TRANSCEND FL: Phase II Study Results of Lisocabtagene Maraleucel (Liso-Cel) in Patients With R/R Follicular Lymphoma (FL)**
Nastoupil, L. J., Dahiya, S., Palomba, M., Martin Garcia-Sancho, A., Reguera Ortega, J., Kuruvilla, J., Jager, U., Cartron, G., Izutsu, K., Dreyling, M., Kahl, B., Ghesquieres, H., Ardeshtna, et al
CIG MEDIA GROUP, LP.2023: S447-S448
 - **Tumor Lysis Syndrome in Leukemias and Lymphomas: A Retrospective Cohort Study of the National Inpatient Sample from 2016 to 2019**
Chitkara, A., Khosla, A., Anamika, F. U., Raj, K., Dahiya, S.
CIG MEDIA GROUP, LP.2023: S444
 - **Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas. *British journal of haematology***
Gao, J., Dahiya, S., Patel, S. A.
2023
 - **Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by 18F-FDG PET/CT Imaging Following CAR-T Therapy. *Clinical lymphoma, myeloma & leukemia***
Lutfi, F., Goloubeva, O., Kowatli, A., Gryaznov, A., Kim, D. W., Dureja, R., Margiotta, P., Matsumoto, L. R., Bukhari, A., Ahmed, N., Mushtaq, M. U., Law, J. Y., Lee, et al
2023
 - **Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD). *Human vaccines & immunotherapeutics***
Kline, K., Chen, W., Kallen, M. E., Koka, R., Omili, D., Fan, X., Iraguha, T., Gebru, E., Dishanthan, N., Baker, J. M., Dietze, K. A., Yared, J. A., Hankey, et al
2023: 2216116

- **Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.** *The New England journal of medicine*
Westin, J. R., Oluwole, O. O., Kersten, M. J., Miklos, D. B., Perales, M. A., Ghobadi, A., Rapoport, A. P., Sureda, A., Jacobson, C. A., Farooq, U., van Meerten, T., Ulrickson, M., Elsayy, et al
2023
- **Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma**
Samples, L. S., Sadrzadeh, H., Frigault, M. J., Jacobson, C., Hamadani, M., Gurumurthi, A., Strati, P., Shouval, R., Riedell, P. A., Dahiya, S., Yared, J., Jain, M. D., Locke, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Circulating Tumor DNA Adds Specificity to PET following Axicabtagene Ciloleucel in Large B-cell Lymphoma.** *Blood advances*
Dean, E. A., Kimmel, G. J., Frank, M. J., Bukhari, A., Hossain, N. M., Jain, M. D., Dahiya, S., Miklos, D. B., Altrock, P. M., Locke, F. L.
2023
- **Second-line treatment with CAR T-cell therapy for large B-cell lymphoma.** *Clinical advances in hematology & oncology : H&O*
Lutfi, F., Patel, A., Mehta, J., Goyal, A., Dahiya, S.
2023; 21 (4): 170-178
- **Second-line Treatment With CAR T-Cell Therapy for Large B-Cell Lymphoma** *CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY*
Lutfi, F., Patel, A., Mehta, J., Goyal, A., Dahiya, S.
2023; 21 (4): 170-178
- **Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Wang, Y., Jain, P., Locke, F. L., Maurer, M. J., Frank, M. J., Munoz, J. L., Dahiya, S., Beitinjaneh, A. M., Jacobs, M. T., Mcguirk, J. P., Vose, J. M., Goy, A., Andreadis, et al
2023: JCO2201797
- **Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes**
Khurana, A., Bailey, M., Iqbal, M., Bansal, R., Lee, C. J., Hunter, B., Lunning, M. A., Jaglowski, S., Jain, M. D., Dahiya, S., Bachanova, V., Farooq, U., Ahmed, et al
AMER SOC HEMATOLOGY.2022: 4657-4660
- **Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects**
Hamilton, M. P., Liu-Fei, F. C., Alig, S. K., Tamaresis, J., Esfahani, M., Good, Z., Sworder, B., Schroers-Martin, J., Liu, C., Severinsen, F., Hanson, P. J., Lu, Y., Lowsky, et al
AMER SOC HEMATOLOGY.2022: 7545-7547
- **The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes**
Philip, S., Srinagesh, H. K., Hamilton, M. P., Gentile, C., Mina, A., Arai, S., Johnston, L. J., Lowsky, R., Meyer, E. H., Negrin, R. S., Rezvani, A. R., Shiraz, P., Shizuru, et al
AMER SOC HEMATOLOGY.2022: 12775-12777
- **Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma**
Bharadwaj, S., Hamilton, M. P., Sahaf, B., Tamaresis, J., Patil, S., Hanson, P. J., Latchford, T., Arai, S., Johnston, L. J., Lowsky, R., Negrin, R. S., Rezvani, A. R., Shizuru, et al
AMER SOC HEMATOLOGY.2022: 10371-10373
- **A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma**
Perales, M., Ahmed, S., Dahiya, S., Riedell, P. A., McGuirk, J. P., Oluwole, O. O., Chaudhry, S. A., Lee, Z., Dai, S., Dixit, N., Fanton, C., Marcondes, M. Q., Zalevsky, et al
AMER SOC HEMATOLOGY.2022: 7488-7490
- **Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.** *Blood*
Elsawy, M., Chavez, J. C., Avivi, I., Larouche, J. F., Wannesson, L., Cwynarski, K., Osman, K., Davison, K., Rudzki, J. D., Dahiya, S., Dorritie, K. A., Jaglowski, S. M., Radford, et al
2022

- **Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapy.** *Blood*
Atanackovic, D., Luetkens, T., Omili, D., Iraguha, T., Lutfi, F., Hardy, N. M., Fan, X., Avila, S. V., Saharia, K. K., Husson, J. S., Niederhaus, S. V., Margiotta, P., Lee, et al
2022; 140 (2): 152-156
- **T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine.** *Journal for immunotherapy of cancer*
Atanackovic, D., Kreitman, R. J., Cohen, J., Hardy, N. M., Omili, D., Iraguha, T., Burbelo, P. D., Gebru, E., Fan, X., Baddley, J., Luetkens, T., Dahiya, S., Rapoport, et al
2022; 10 (7)
- **KITE-363: A phase 1 study of an autologous anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) B-cell lymphoma (BCL).**
Nastoupil, L. J., Dahiya, S., Miklos, D., Reagan, P., Ulrickson, M., Jung, A., Kloos, I., Dong, J., Chou, J., Murakami, J., Rodriguez, K., Nahas, M. LIPPINCOTT WILLIAMS & WILKINS.2022
- **The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma.** *Clinical lymphoma, myeloma & leukemia*
Nuvvula, S., Dahiya, S., Patel, S. A.
2022; 22 (6): 362-372
- **Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma.** *Leukemia & lymphoma*
Kim, D. W., Bukhari, A., Lutfi, F., Zaffroni, F., Merechi, F., Mustafa Ali, M. K., Gottlieb, D., Lee, S. T., Kocoglu, M. H., Hardy, N. M., Yared, J., Rapoport, A. P., Dahiya, et al
2022; 63 (6): 1339-1347
- **Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: Real-world experience from the United States lymphoma CAR T consortium.**
Jain, P., Wang, Y., Locke, F. L., Munoz, J., Beitinjaneh, A., Frank, M., Dahiya, S., Jacobs, M. T., Hill, B. T., Lekakis, L. J., Miklos, D., Ghobadi, A., Neelapu, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium.** *Clinical lymphoma, myeloma & leukemia*
Jacobs, M. T., Jain, M. D., Gao, F., Nastoupil, L. J., Spiegel, J. Y., Lin, Y., Dahiya, S., Lunning, M., Lekakis, L., Reagan, P. M., Oluwole, O. O., McGuirk, J., Deol, et al
2022
- **Humoral immunity against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccine.** *Clinical & translational immunology*
Saharia, K. K., Husson, J. S., Niederhaus, S. V., Iraguha, T., Avila, S. V., Yoo, Y. J., Hardy, N. M., Fan, X., Omili, D., Crane, A., Carrier, A., Xie, W. Y., Vander Mause, et al
2022; 11 (5): e1391
- **Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review.** *The British journal of ophthalmology*
Mumtaz, A. A., Fischer, A., Lutfi, F., Matsumoto, L. R., Atanackovic, D., Kolanci, E. T., Hankey, K. G., Hardy, N. M., Yared, J. A., Kocoglu, M. H., Rapoport, A. P., Dahiya, S., Li, et al
2022
- **Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy.** *Blood advances*
Dahiya, S., Luetkens, T., Lutfi, F., Avila, S., Iraguha, T., Margiotta, P., Hankey, K. G., Lesho, P., Law, J. Y., Lee, S. T., Baddley, J., Kocoglu, M., Yared, et al
2022; 6 (2): 686-689
- **Deep dissection of the antiviral immune profile of patients with COVID-19.** *Communications biology*
Atanackovic, D., Avila, S. V., Lutfi, F., de Miguel-Perez, D., Fan, X., Sanchez-Petitto, G., Vander Mause, E., Siglin, J., Baddley, J., Mannuel, H. D., Alkhaldi, H., Hankey, K. G., Lapidus, et al
2021; 4 (1): 1389

- **Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.** *The New England journal of medicine*
Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M., Kersten, M., Oluwole, O. O., Ghobadi, A., Rapoport, A. P., McGuirk, J., Pagel, J. M., Munoz, J., Farooq, U., van Meerten, et al
2021
- **Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium**
Spiegel, J. Y., Jain, M. D., Nastoupil, L., Tamaresis, J., Ghobadi, A., Lin, Y., Lekakis, L. J., Reagan, P. M., Oluwole, O. O., McGuirk, J. P., Deol, A., Sehgal, A. R., Goy, et al
AMER SOC HEMATOLOGY.2021: 3826-+
- **Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium**
Wang, Y., Jain, P., Locke, F. L., Munoz, J., Maurer, M. J., Beitinjaneh, A., Frank, M. J., Dahiya, S., McGuirk, J. P., Jacobs, M. T., Goy, A. H., Vose, J. M., Hill, et al
AMER SOC HEMATOLOGY.2021
- **The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.** *British journal of haematology*
Lutfi, F., Holtzman, N. G., Kansagra, A. J., Mustafa Ali, M., Bukhari, A., Yan, J., Samanta, S., Gottlieb, D., Kim, D. W., Matsumoto, L. R., Gahres, N., Ruehle, K., Lee, et al
2021; 195 (3): 405-412
- **Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant.** *Vaccines*
Atanackovic, D., Luetkens, T., Avila, S. V., Hardy, N. M., Lutfi, F., Sanchez-Petitto, G., Vander Mause, E., Glynn, N., Manuel, H. D., Alkhalidi, H., Hankey, K., Baddley, J., Dahiya, et al
2021; 9 (7)
- **Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Frank, M. J., Hossain, N. M., Bukhari, A., Dean, E., Spiegel, J. Y., Claire, G. K., Kirsch, I., Jacob, A. P., Mullins, C. D., Lee, L. W., Kong, K. A., Craig, J., Mackall, et al
2021: JCO2100377
- **Length of Stay and Hospital Costs for Patients Undergoing Allogeneic Stem-Cell Transplantation.** *JCO oncology practice*
Godara, A., Siddiqui, N. S., Munigala, S., Dhawan, R., Kansagra, A. J., Rapoport, A. P., Yared, J. A., Dahiya, S.
2021; 17 (3): e355-e368
- **The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement.** *Leukemia research*
Bergstrom, C. P., Dahiya, S., Chen, W., Zhang, C. C., Zhu, H., Yan, J., Madanat, Y., Patel, P., Vusirkala, M., Ramakrishnan, P., Rizvi, S., Chung, S., Awan, et al
2021; 100: 106480
- **Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma.** *British journal of haematology*
Lutfi, F., Holtzman, N., Siglin, J., Bukhari, A., Mustafa Ali, M., Kim, D., Sanchez-Petitto, G., Gottlieb, D., Ruehle, K., Hutnick, E., Gahres, N., Hankey, K., Lee, et al
2021; 192 (1): 212-216
- **Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel.** *Blood*
Spiegel, J. Y., Dahiya, S., Jain, M. D., Tamaresis, J. S., Nastoupil, L., Jacobs, M. T., Ghobadi, A., Lin, Y., Lunning, M., Lekakis, L. J., Reagan, P., Oluwole, O. O., McGuirk, et al
2020
- **Severe dysautonomia as a manifestation of neurotoxicity after CAR-T cell therapy for diffuse large B-cell lymphoma.** *American journal of hematology*
El Chaer, F., Siegel, A., Holtzman, N. G., Bukhari, A., Lutfi, F., Shah, N. G., Yared, J. A., Rapoport, A. P., McCurdy, M. T., Dahiya, S.
2020; 95 (6): E146-E148
- **Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*

- Nastoupil, L. J., Jain, M. D., Feng, L., Spiegel, J. Y., Ghobadi, A., Lin, Y., Dahiya, S., Lunning, M., Lekakis, L., Reagan, P., Oluwole, O., McGuirk, J., Deol, et al
2020: JCO1902104
- **Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.** *Lancet (London, England)*
Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y. n., Rubinstein, S. M., Rivera, D. R., Shete, S. n., Hsu, C. Y., Desai, A. n., de Lima Lopes, G. n., Grivas, P. n., Painter, C. A., Peters, et al
2020
 - **Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.** *International journal of radiation oncology, biology, physics*
Sim, A. J., Jain, M. D., Figura, N. B., Chavez, J. C., Shah, B. D., Khimani, F., Lazaryan, A., Krivenko, G., Davila, M. L., Liu, H. D., Falchook, A. D., Dahiya, S., Rapoport, et al
2019; 105 (5): 1012-1021
 - **Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma**
Frank, M. J., Hossain, N., Bukhari, A., Dean, E., Spiegel, J. Y., Claire, G. K., Kirsch, I. M., Jacob, A. P., Mullins, C. D., Lee, L., Kong, K. A., Craig, J., Mackall, et al
AMER SOC HEMATOLOGY.2019
 - **Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium**
Jain, M. D., Jacobs, M. T., Nastoupil, L. J., Spiegel, J. Y., Feng, G., Lin, Y., Lunning, M. A., Dahiya, S., Lekakis, L. J., Reagan, P. M., Oluwole, O. O., McGuirk, J. P., Deol, et al
AMER SOC HEMATOLOGY.2019
 - **Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium**
Bennani, N., Maurer, M. J., Nastoupil, L. J., Jain, M. D., Chavez, J. C., Cashen, A. F., Dahiya, S., Lekakis, L. J., Reagan, P. M., Oluwole, O. O., McGuirk, J. P., Deol, A., Sehgal, et al
AMER SOC HEMATOLOGY.2019
 - **Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss.** *American journal of hematology*
Bukhari, A., El Chaer, F., Koka, R., Singh, Z., Hutnick, E., Ruehle, K., Lee, S. T., Kocoglu, M. H., Shanholtz, C., Badros, A., Hardy, N., Yared, J., Rapoport, et al
2019; 94 (10): E273-E275
 - **Refractory postallogeic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab.** *American journal of hematology*
Bathini, S., Holtzman, N. G., Koka, R., Singh, Z., Wilding, E., Zou, Y., Ruehle, K., Kocoglu, M. H., Badros, A., Hardy, N., Yared, J., Rapoport, A. P., Fontaine, et al
2019; 94 (8): E216-E219
 - **Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis.**
Frank, M., Hossain, N. M., Bukhari, A., Dean, E., Spiegel, J. Y., Claire, G. K., Kirsch, I., Jacob, A., Mullins, C. D., Lee, L., Kong, K. A., Craig, J. K., Mackall, et al
AMER SOC CLINICAL ONCOLOGY.2019
 - **Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy** *LEUKEMIA & LYMPHOMA*
Hossain, N. M., Dahiya, S., Le, R., Abramian, A. M., Kong, K. A., Muffly, L. S., Miklos, D. B.
2019; 60 (2): 503-506
 - **Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy.** *Leukemia & lymphoma*
Hossain, N. M., Dahiya, S., Le, R., Abramian, A. M., Kong, K. A., Muffly, L. S., Miklos, D. B.
2018: 1-4
 - **Continuing challenges and current issues in acute lymphoblastic leukemia** *LEUKEMIA & LYMPHOMA*
Kansagra, A., Dahiya, S., Litzow, M.
2018; 59 (3): 526-41

- **Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR-T therapy.**
Dahiya, S., Le, R., Hossain, N., Abramian, M., Muffly, L. S., Miklos, D.
AMER SOC CLINICAL ONCOLOGY.2017
- **Correlation of higher levels of soluble TNF-R1 with a shorter survival, independent of age, in recurrent glioblastoma.** *Journal of neuro-oncology*
Ahluwalia, M. S., Bou-Anak, S., Burgett, M. E., Sarmey, N., Khosla, D., Dahiya, S., Weil, R. J., Bae, E., Huang, P., McGraw, M., Grove, L. M., Olman, M. A., Prayson, et al
2016
- **Treatment of Cerebral Radiation Necrosis With Bevacizumab: The Cleveland Clinic Experience** *AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS*
Sadraei, N. H., Dahiya, S., Chao, S. T., Murphy, E. S., Osei-Boateng, K., Xie, H., Suh, J. H., Peereboom, D. M., Stevens, G. H., Ahluwalia, M. S.
2015; 38 (3): 304-310
- **Bevacizumab in high-grade gliomas: past, present, and future.** *Expert review of anticancer therapy*
Curry, R. C., Dahiya, S., Alva Venur, V., Raizer, J. J., Ahluwalia, M. S.
2015; 15 (4): 387-397
- **Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.** *Journal of neuro-oncology*
Ahluwalia, M. S., Xie, H., Dahiya, S., Hashemi-Sadraei, N., Schiff, D., Fisher, P. G., Chamberlain, M. C., Pannullo, S., Newton, H. B., Brewer, C., Wood, L., Prayson, R., Elson, et al
2015; 122 (1): 111-119
- **Sleep disturbances in cancer patients: Underrecognized and undertreated** *CLEVELAND CLINIC JOURNAL OF MEDICINE*
Dahiya, S., Ahluwalia, M. S., Walia, H. K.
2013; 80 (11): 722-732
- **Recurrent or refractory primary central nervous lymphoma: therapeutic considerations** *EXPERT REVIEW OF ANTICANCER THERAPY*
Dahiya, S., Murphy, E. S., Chao, S. T., Stevens, G. H., Peereboom, D. M., Ahluwalia, M. S.
2013; 13 (9): 1109-1119
- **Primary Central Nervous System Lymphoma in the Elderly: The Cleveland Clinic Experience** *ANTICANCER RESEARCH*
Xie, H., Dahiya, S., Murphy, E. S., Chao, S. T., Suh, J. H., Stevens, G. H., Peereboom, D. M., Ahluwalia, M. S.
2013; 33 (8): 3251-3258
- **Primary central nervous system posttransplantation lymphoproliferative disorder in an elderly liver transplant recipient.** *Journal of the American Geriatrics Society*
Dahiya, S., Ooi, W. B., Ahluwalia, M. S., Asik, A.
2012; 60 (9): 1777-8